A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Cabotegravir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms POLAR
- Sponsors ViiV Healthcare
- 19 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2019 Planned End Date changed from 30 Nov 2020 to 11 Jan 2021.
- 14 Feb 2019 Planned primary completion date changed from 2 Dec 2019 to 13 Jan 2020.